Du är här


Sanofi : Sanofi Reaches Patent Settlement on Lantus® SoloSTAR®

Sanofi Reaches Patent Settlement on Lantus®SoloSTAR®

Paris, France - September 28, 2015
Sanofi announced today that it has reached a settlement agreement with Eli
Lilly and Company ("Lilly"), which addresses patents on Sanofi's
Lantus®SoloSTAR®(insulin glargine). The agreement resolves a U.S. patent
infringement lawsuit regarding Lilly's pursuit of regulatory approval for a
product that would compete with Lantus SoloSTAR. Sanofi and Lilly agreed to
end that lawsuit and to discontinue similar disputes worldwide.

Under the agreement, Lilly will pay royalties to Sanofi in exchange for a
license to certain Sanofi patents. In the U.S., Lilly will not sell its
insulin glargine product before December 15, 2016. The agreement does not
include Lantus (vial), Toujeo®or combination products. The remaining
settlement terms are confidential.

Sanofi will continue its commitment to develop and deliver innovations for the
more than 387 million people globally living with diabetes.

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT:SAN) and in New York (NYSE:SNY).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and similar
expressions. Although Sanofi's management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in
research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment policies and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the
year ended December 31, 2014. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.

| Media Relations Investor Relations |
| |
|Mary Kathryn Steel Sébastien Martel |
|Tel. : +1 908-989-0726 Tel.: +33 (0)1 53 77 45 45 |
|usmediarelations@sanofi.com ir@sanofi.com |
Click here for high-definition image files for Lantus® SoloSTAR®

Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.